Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics


Corcept Therapeutics Incorporated (CORT): $20.42

0.17 (+0.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CORT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CORT POWR Grades


  • CORT scores best on the Quality dimension, with a Quality rank ahead of 99.57% of US stocks.
  • The strongest trend for CORT is in Stability, which has been heading down over the past 179 days.
  • CORT's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

CORT Stock Summary

  • The ratio of debt to operating expenses for Corcept Therapeutics Inc is higher than it is for about merely 4.94% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for Corcept Therapeutics Inc; that's greater than it is for only 8.1% of US stocks.
  • With a year-over-year growth in debt of -79.38%, Corcept Therapeutics Inc's debt growth rate surpasses only 3.19% of about US stocks.
  • Stocks that are quantitatively similar to CORT, based on their financial statements, market capitalization, and price volatility, are HRTX, CCXI, QUIK, OLED, and BLI.
  • CORT's SEC filings can be seen here. And to visit Corcept Therapeutics Inc's official web site, go to www.corcept.com.

CORT Valuation Summary

  • In comparison to the median Healthcare stock, CORT's EV/EBIT ratio is 24.23% lower, now standing at 22.2.
  • CORT's EV/EBIT ratio has moved up 50.1 over the prior 212 months.
  • CORT's price/sales ratio has moved NA NA over the prior 212 months.

Below are key valuation metrics over time for CORT.

Stock Date P/S P/B P/E EV/EBIT
CORT 2021-08-31 7.2 4.7 25.3 22.2
CORT 2021-08-30 7.3 4.8 25.6 22.5
CORT 2021-08-27 7.3 4.8 25.6 22.5
CORT 2021-08-26 7.1 4.7 25.1 22.0
CORT 2021-08-25 7.1 4.7 25.1 22.1
CORT 2021-08-24 7.1 4.7 25.1 22.1

CORT Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 107.34%.
  • The 3 year price growth rate now stands at 140.21%.
  • Its year over year cash and equivalents growth rate is now at -37.99%.
CORT's revenue has moved up $9,944,000 over the prior 15 months.

The table below shows CORT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 365.978 167.892 112.512
2021-09-30 352.891 153.536 106.453
2021-06-30 343.087 135.276 97.607
2021-03-31 340.064 144.123 99.411
2020-12-31 353.874 151.97 106.011
2020-09-30 356.034 165.353 109.398

CORT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CORT has a Quality Grade of A, ranking ahead of 98.86% of graded US stocks.
  • CORT's asset turnover comes in at 0.616 -- ranking 52nd of 681 Pharmaceutical Products stocks.
  • OTIC, ABT, and AVDL are the stocks whose asset turnover ratios are most correlated with CORT.

The table below shows CORT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.616 0.985 0.237
2021-03-31 0.631 0.985 0.248
2020-12-31 0.691 0.984 0.312
2020-09-30 0.754 0.984 0.345
2020-06-30 0.816 0.983 0.413
2020-03-31 0.862 0.982 0.432

CORT Price Target

For more insight on analysts targets of CORT, see our CORT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.25 Average Broker Recommendation 1.75 (Moderate Buy)

CORT Stock Price Chart Interactive Chart >

Price chart for CORT

CORT Price/Volume Stats

Current price $20.42 52-week high $25.68
Prev. close $20.25 52-week low $15.82
Day low $19.90 Volume 1,170,200
Day high $20.63 Avg. volume 946,665
50-day MA $22.53 Dividend yield N/A
200-day MA $20.97 Market Cap 2.17B

Corcept Therapeutics Incorporated (CORT) Company Bio


Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.


CORT Latest News Stream


Event/Time News Detail
Loading, please wait...

CORT Latest Social Stream


Loading social stream, please wait...

View Full CORT Social Stream

Latest CORT News From Around the Web

Below are the latest news stories about Corcept Therapeutics Inc that investors may wish to consider to help them evaluate CORT as an investment opportunity.

3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin

When it comes to high-flying cryptocurrencies, Shiba Inu (CRYPTO: SHIB) is among the most visible. Fueled by a frenzy of speculative buying late last year, the cheerful memes minted by the coin's community, known as the Shiba Army, are doubtlessly one of its enduring appeals. On the other hand, you probably haven't heard of Corcept Therapeutics (NASDAQ: CORT), a biotech company that's worth just over $2.6 billion.

Yahoo | February 23, 2022

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff On Q4 2021 Results - Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q4 2021 Results Conference Call February 15, 2022 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Sean Maduck - Chief Commercial Officer Bill Guyer - Chief Development Officer Conference Call Participants...

SA Transcripts on Seeking Alpha | February 16, 2022

Analysts’ Top Healthcare Picks: Corcept Therapeutics (CORT), Stealth Biotherapeutics (MITO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments. Corcept Therapeutics (CORT) H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company's shares closed last Tuesday at $20.31. According to TipRanks.

Brian Anderson on TipRanks | February 16, 2022

Corcept Therapeutics (CORT) Q4 2021 Earnings Call Transcript

CORT earnings call for the period ending December 31, 2021.

The Motley Fool | February 16, 2022

Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss

Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.

Yahoo | February 16, 2022

Read More 'CORT' Stories Here

CORT Price Returns

1-mo -11.18%
3-mo -9.41%
6-mo -10.71%
1-year -5.29%
3-year 92.64%
5-year 73.34%
YTD 3.13%
2021 -24.31%
2020 116.20%
2019 -9.43%
2018 -26.02%
2017 148.76%

Continue Researching CORT

Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:

Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9467 seconds.